USRE38520E1 - Erythromycin derivatives, method for preparing same, and use thereof as drugs - Google Patents

Erythromycin derivatives, method for preparing same, and use thereof as drugs Download PDF

Info

Publication number
USRE38520E1
USRE38520E1 US09/838,628 US83862801A USRE38520E US RE38520 E1 USRE38520 E1 US RE38520E1 US 83862801 A US83862801 A US 83862801A US RE38520 E USRE38520 E US RE38520E
Authority
US
United States
Prior art keywords
compound
methyl
dideoxy
alkyl
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09/838,628
Inventor
Constantin Agouridas
Jean-Francois Chantot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9602472A external-priority patent/FR2745290B1/en
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to US09/838,628 priority Critical patent/USRE38520E1/en
Application granted granted Critical
Publication of USRE38520E1 publication Critical patent/USRE38520E1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Definitions

  • the present invention relates to new erythromycin derivatives, their preparation process and their use as medicaments.
  • a subject of the invention is the compounds of formula (I):
  • X represents a CH 2 or SO 2 radical or an oxygen atom
  • Ar represents an optionally substituted aryl radical
  • W represents a hydrogen atom, or the remainder of a carbamate function
  • R′′ represents an alkyl radical containing up to 8 carbon atoms or an optionally substituted aryl radical
  • Z represents a hydrogen atom or the remainder of an acid, as well as their addition salts with acids.
  • salts formed with the following acids there can be can mentioned the salts formed with the following acids: acetic, propionic, trifluoroacetic, maleic, tartaric, methanesulphonic, benzenesulphonic, p-toluenesulphonic, and in particular stearic, ethylsuccinic or laurylsulphonic.
  • the aryl radical can be a phenyl or naphthyl radical.
  • the aryl radical can also be a substituted or non-substituted heterocyclic radical such as the thienyl, furyl, pyrolyl, thiazolyl, oxazolyl, imidazolyl, thiadiazolyl, pyrazolyl or isopyrazolyl radical, a pyridyl, pyrimidyl, pyridazinyl or pyrazinyl radical, or also an indolyl benzofurannyl, benzothiazyl or quinolinyl radical.
  • a substituted or non-substituted heterocyclic radical such as the thienyl, furyl, pyrolyl, thiazolyl, oxazolyl, imidazolyl, thiadiazolyl, pyrazolyl or isopyrazolyl radical, a pyridyl, pyrimidyl, pyridazinyl or pyrazinyl radical, or also
  • aryl radicals can contain one or more groups chosen from the group constituted by hydroxyl radicals, halogen atoms, NO 2 radicals C ⁇ N radicals, alkyl, alkenyl or alkynyl, O-alkyl, O-alkenyl or O-alkynyl, S-alkyl, S-alkenyl or S-alkynyl and N-alkyl, N-alkenyl or N-alkynyl radicals, containing up to 12 carbon atoms optionally substituted by one or more halogen atoms, the group constituted by hydroxyl radicals, halogen atoms, NO 2 radicals C ⁇ N radicals, alkyl, alkenyl or alkynyl, O-alkyl, O-alkenyl or O-alkynyl, S-alkyl, S-alkenyl or S-alkynyl and N-alkyl, N-alkenyl or N-alkynyl radicals,
  • R a and R b identical or different, representing a hydrogen atom or an alkyl radical containing up to 12 carbon atoms
  • R 3 representing an alkyl radical containing up to 12 carbon atoms, or an optionally substituted aryl or heteroaryl radical, the following radicals: carboxylic aryl, O-aryl or S-aryl or heterocyclic aryl, O-aryl or S-aryl with 5 or 6 members containing one or more heteroatoms, optionally substituted by one or more of the substituents mentioned hereafter.
  • These preferred heterocyclic radicals can be substituted by one or more functional groups.
  • a more particular subject of the invention is the compounds of formula (I) in which Z represents a hydrogen atom, these in which W represents a hydrogen atom, those in which X represents a CH 2 radical, those in which Y represents a (CH 2 ) 3 , (CH 2 ) 4 or (CH 2 ) 5 radical.
  • the products of general formula (I) have a very good antiobiotic activity of gram + bacteria such as staphylococci, streptococci, pneumococci.
  • the compounds of the invention can therefore be used as medicaments in the treatment of infections caused by susceptible germs and in particular, in that of staphylococcal infections, such as staphylococcal septicemias, malignant staphylococcal infections of the face of skin, pyodermatitis, septic or suppurating sores, boils, anthrax, phlegmons, erysipelas and acne, staphylococcia such as acute primary or post-influenzal angina, bronchopneumonia, pulmonary suppuration, streptococcal infections such as acute anginas, otitis, sinusitis, scarlet fever, pneumococcal infections such as pneumonia, bronchitis; brucellosis, diphtheria, gonococcal infection.
  • staphylococcal infections such as staphylococcal septicemias, malignant staphylococcal infections of the face of skin, pyodermatitis, septic or
  • the products of the present invention are also active against infections caused by germs such as Haemophilus influenzae, Rickettsies, Mycoplasma, pneumoniae, Chlamydia, Legionella, Ureaplasma, Toxoplasma or by germs of the Mycobacterium genus.
  • a subject of the present invention is, as medicaments and in particular antibiotic medicaments, the products of formula (I) as defined above, as well as their addition salts with pharmaceutically acceptable mineral or organic acids.
  • a more particular subject of the invention is, as medicaments and in particular antibiotic medicaments, the products of Examples 1 or 2 and their pharmaceutically acceptable salts.
  • a subject of the invention is also the pharmaceutical compositions containing at least one of the medicaments defined above as active ingredient.
  • compositions can be administered by buccal, rectal, parenteral route or by local route as a topical application on the skin and mucous membranes, but the preferred administration route is the buccal route.
  • compositions commonly used in human medicine such as for example, plain or sugar-coated tablets, capsules, granules, suppositories, injectable preparations, ointments, creams, gels; they are prepared according to the usual methods.
  • the active ingredient or ingredients can be incorporated with excipients usually employed in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or non-aqeuous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting, dispersing or emulsifying agents, preservatives.
  • compositions can also be presented in the form of a powder intended to be dissolved extemporaneously in an appropriate vehicle, for example apyrogenic sterile water.
  • the dose administered is variable according to the illness treated, the patient in question, the administration route and the product considered. It can be, for example, comprised between 50 mg and 500 mg per day by oral route, for an adult for the product of Example 1 or Example 2.
  • a subject of the invention is also a preparation process, characterized in that a compound of formula (II):
  • X, Y and Ar retain their previous meaning, which is subjected, if desired, to the action of an esterification agent or to the action of an agent capable of introducing the carbamate radical.
  • the cleavage of cladinose in position 3 is carried out using an acid.
  • the products of formula (II) used as starting products are products which can be prepared according to the process described in the European Patent Application 076093 filed on Dec. 6, 1995 by the Company ROUSSEL UCLAF.
  • R 3 represents the X—Y—Ar radical, X, Y and Ar being defined as previously in order to obtain the compound of formula (V):
  • the amines of formula (IV) are known in a general way and can be prepared according to the processes described in J. Med. Chem. (1982) Vol. 25, p. 947 and subsequent or also Tetrahedron Letters Vol. 32 No. 14, p. 1699, 1702 (1991).
  • the cleavage of the acetate in position 2′′ is carried out using methanol.
  • the cleavage of the benzyloxycarbonyl group in position 4′′ is carried out by reduction, for example using hydrogen in the presence of a palladium catalyst.
  • the salification is carried out using an acid according to standard processes.
  • the product obtained in Stage b) is dissolved in 100 ml of methanol. Hydrogeneolysis is carried out in the presence of 600 mg of 10% palladium on activated charcoal, followed by filtering, rinsing with methanol and methylene chloride then the filtrate is concentrated to dryness. 2.52 g of a product is obtained which is purified by eluting with an isopropryl ether-menthanol-triethylamine mixture (80-10-10). 941.8 mg of a product is obtained which is chromatographed again eluting with an isopropyl ether-methanol-triethylamine mixture (80-10-10). In this way 761 mg of 6-O-methyl-12,11-(oxycarbonyl) (2-hydrazono)) erythromycin is obtained.
  • a mixture of 230 mg of the product obtained in Stage A above, 5 ml of methanol, 0.3 g of quinoline 4-propanal, 0.055 ml of acetic acid is agitated for 15 hours of ambient temperature. 0.065 g of sodium cyanoborohydride is added. Agitation is carried out at ambient temperature for 24 hours.
  • the methanol is evaporated off, followed by extracting with ethyl acetate, washing with soda solution then with water, drying, filtering and evaporating to dryness. 220 mg of a product is obtained which is chromatographed on silica, eluting with an ethyl acetate-triethylamine mixture (95-5). 80 mg of the sought product is obtained.
  • the starting product namely 11,12-dideoxy-6-O-methyl-12,11-(oxycarbonyl((4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)imino))-erythromycin was prepared according to the process indicated above the preparation of the starting product of Example 1.
  • a series of tubes were prepared into which the same quantity of sterile nutritive medium is distributed. Increasing quantities of the product to be studied are distributed into each tube, then each tube is seeded with a bacterial strain. After incubation for twenty-four hours in a heating chamber at 37° C., the growth inhibition is evaluated by transillumination, which permits the minimal inhibitory concentrations (M.I.C.) to be determined, expressed in micrograms/cm 3 .
  • M.I.C. minimal inhibitory concentrations

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

A subject of the invention is the compounds of formula (I):
Figure USRE038520-20040518-C00001
in which:
X represents a CH2 or SO2 radical or an oxygen atom, Y represents a (CH2)m—(CH═CH)n(CH2)o radical, with m+n+o≦8, n=0 or 1, Ar represents an aryl radical,
W represents a hydrogen atom, or the remainder of a carbamate function.
The compounds of formula (I) have useful antibiotic properties.

Description

This application is the U.S. national stage entry under 35 U.S.C. 371 of PCT/FR97/00351, filed Feb. 27, 1997.
The present invention relates to new erythromycin derivatives, their preparation process and their use as medicaments.
A subject of the invention is the compounds of formula (I):
Figure USRE038520-20040518-C00002
in which:
X represents a CH2or SO2 radical or an oxygen atom, Y represents a (CH2)m—(CH═CH)n(CH2)o radical, with m+n+o≦8, n=0 or 1.
Ar represents an optionally substituted aryl radical,
W represents a hydrogen atom, or the remainder of a carbamate function
Figure USRE038520-20040518-C00003
in which R″ represents an alkyl radical containing up to 8 carbon atoms or an optionally substituted aryl radical,
Z represents a hydrogen atom or the remainder of an acid, as well as their addition salts with acids.
Among the addition salts with acids, there can be can mentioned the salts formed with the following acids: acetic, propionic, trifluoroacetic, maleic, tartaric, methanesulphonic, benzenesulphonic, p-toluenesulphonic, and in particular stearic, ethylsuccinic or laurylsulphonic.
The aryl radical can be a phenyl or naphthyl radical.
The aryl radical can also be a substituted or non-substituted heterocyclic radical such as the thienyl, furyl, pyrolyl, thiazolyl, oxazolyl, imidazolyl, thiadiazolyl, pyrazolyl or isopyrazolyl radical, a pyridyl, pyrimidyl, pyridazinyl or pyrazinyl radical, or also an indolyl benzofurannyl, benzothiazyl or quinolinyl radical.
These aryl radicals can contain one or more groups chosen from the group constituted by hydroxyl radicals, halogen atoms, NO2 radicals C≡N radicals, alkyl, alkenyl or alkynyl, O-alkyl, O-alkenyl or O-alkynyl, S-alkyl, S-alkenyl or S-alkynyl and N-alkyl, N-alkenyl or N-alkynyl radicals, containing up to 12 carbon atoms optionally substituted by one or more halogen atoms, the
Figure USRE038520-20040518-C00004
Ra and Rb, identical or different, representing a hydrogen atom or an alkyl radical containing up to 12 carbon atoms, the
Figure USRE038520-20040518-C00005
R3 representing an alkyl radical containing up to 12 carbon atoms, or an optionally substituted aryl or heteroaryl radical, the following radicals: carboxylic aryl, O-aryl or S-aryl or heterocyclic aryl, O-aryl or S-aryl with 5 or 6 members containing one or more heteroatoms, optionally substituted by one or more of the substituents mentioned hereafter.
As preferred heterocycle, there can be mentioned among others:
Figure USRE038520-20040518-C00006
Figure USRE038520-20040518-C00007
and the heterocyclic radicals envisaged in the European Patent Applications 487411, 596802, 676409 and 680967. These preferred heterocyclic radicals can be substituted by one or more functional groups.
A more particular subject of the invention is the compounds of formula (I) in which Z represents a hydrogen atom, these in which W represents a hydrogen atom, those in which X represents a CH2 radical, those in which Y represents a (CH2)3, (CH2)4 or (CH2)5 radical.
Among the preferred compounds of the invention, there can be mentioned the compounds of formula (I), in which Ar represents a heterocyclic aryl radical, such as for example those in which Ar represents a 4-quinolinyl radical optionally mono- or polysubstituted on one and/or the other of the 2 quinoline rings, and quite particularly the compounds of formula (I) in which AR represents a non-substituted 4-quinolinyl radical, or also for example the compounds of formula (I), in which Ar represents an optionally substituted:
Figure USRE038520-20040518-C00008
Among the preferred compounds of the invention, there can naturally be mentioned the products whose preparation is given hereafter in the experimental part.
The products of general formula (I) have a very good antiobiotic activity of gram+ bacteria such as staphylococci, streptococci, pneumococci.
The compounds of the invention can therefore be used as medicaments in the treatment of infections caused by susceptible germs and in particular, in that of staphylococcal infections, such as staphylococcal septicemias, malignant staphylococcal infections of the face of skin, pyodermatitis, septic or suppurating sores, boils, anthrax, phlegmons, erysipelas and acne, staphylococcia such as acute primary or post-influenzal angina, bronchopneumonia, pulmonary suppuration, streptococcal infections such as acute anginas, otitis, sinusitis, scarlet fever, pneumococcal infections such as pneumonia, bronchitis; brucellosis, diphtheria, gonococcal infection.
The products of the present invention are also active against infections caused by germs such as Haemophilus influenzae, Rickettsies, Mycoplasma, pneumoniae, Chlamydia, Legionella, Ureaplasma, Toxoplasma or by germs of the Mycobacterium genus.
Therefore a subject of the present invention is, as medicaments and in particular antibiotic medicaments, the products of formula (I) as defined above, as well as their addition salts with pharmaceutically acceptable mineral or organic acids.
A more particular subject of the invention is, as medicaments and in particular antibiotic medicaments, the products of Examples 1 or 2 and their pharmaceutically acceptable salts.
A subject of the invention is also the pharmaceutical compositions containing at least one of the medicaments defined above as active ingredient.
These compositions can be administered by buccal, rectal, parenteral route or by local route as a topical application on the skin and mucous membranes, but the preferred administration route is the buccal route.
They can be solid or liquid and be presented in the pharmaceutical forms commonly used in human medicine, such as for example, plain or sugar-coated tablets, capsules, granules, suppositories, injectable preparations, ointments, creams, gels; they are prepared according to the usual methods. The active ingredient or ingredients can be incorporated with excipients usually employed in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or non-aqeuous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting, dispersing or emulsifying agents, preservatives.
These compositions can also be presented in the form of a powder intended to be dissolved extemporaneously in an appropriate vehicle, for example apyrogenic sterile water.
The dose administered is variable according to the illness treated, the patient in question, the administration route and the product considered. It can be, for example, comprised between 50 mg and 500 mg per day by oral route, for an adult for the product of Example 1 or Example 2.
A subject of the invention is also a preparation process, characterized in that a compound of formula (II):
Figure USRE038520-20040518-C00009
in which X, Y and Ar are as defined above, is subjected to the action of a cleavage agent of cladinose in order to obtain the corresponding compound of formula (IA):
Figure USRE038520-20040518-C00010
in which X, Y and Ar retain their previous meaning, which is subjected, if desired, to the action of an esterification agent or to the action of an agent capable of introducing the carbamate radical.
In a preferred implementation the cleavage of cladinose in position 3 is carried out using an acid.
The products of formula (II) used as starting products, are products which can be prepared according to the process described in the European Patent Application 076093 filed on Dec. 6, 1995 by the Company ROUSSEL UCLAF.
The products of formula (II) can be prepared according to a process characterized in that a compound of formula (III):
Figure USRE038520-20040518-C00011
in which Bn represents a benzyloxycarbonyl radical and Ac an acyl radical containing 2 to 20 carbon atoms, is subjected to the action of a compound of formula (IV):
R3NH2   (IV)
in which R3 represents the X—Y—Ar radical, X, Y and Ar being defined as previously in order to obtain the compound of formula (V):
Figure USRE038520-20040518-C00012
which is subjected, if desired, to the action of a cleavage agent of the ester function in position 2′ in order to obtain the corresponding 2′—OH compound, then if desired, the compound thus obtained is subjected to the action of a reducing agent in order to carry out the cleavage of the benzyloxy carbonyl group in position 4″ and to obtain the product of formula (II).
The compounds of formula (III) used as starting products are known products desired in the European Patent 0,248,279.
The amines of formula (IV) are known in a general way and can be prepared according to the processes described in J. Med. Chem. (1982) Vol. 25, p. 947 and subsequent or also Tetrahedron Letters Vol. 32 No. 14, p. 1699, 1702 (1991).
The cleavage of the acetate in position 2″ is carried out using methanol.
The cleavage of the benzyloxycarbonyl group in position 4″ is carried out by reduction, for example using hydrogen in the presence of a palladium catalyst.
The salification is carried out using an acid according to standard processes.
The following examples illustrate the invention without however limiting it.
EXAMPLE 1 11,12-dideoxy-3-de((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribohexopyranosyl)oxy)-3-hydroxy-6-O-methyl-12,11-(oxycarbonyl(2-(3-(4-quinolinyl)propyl)hydrazono)) erythromycin
1 cm3 of a solution of hydrochloric acid in ethanol (22 g/l) is added to a solution containing 250 mg of 11,12-dideoxy-6-O-methyl-12,11-(oxycarbonyl(2-(3-(4-quinolinyl)propyl)hydrazono) erythromycin. The reaction mixture is agitated at ambient temperature for one hour. It is poured into water, extracted with ethyl acetate, the aqueous phase is taken up, adjusted to a basic medium, extracted with ethyl acetate, dried, filtered and evaporated to dryness. In this way 271 mg of a product is obtained which is dissolved in ethyl acetate, then sulphuric ether is added until the product crystallizes. After washing with sulphuric ether, 169 mg is obtained which is recrystallized. After drying at 80° C., 120 mg of product melting at 166° C. is obtained.
The product 11,12-dideoxy-6-O-methyl-12,11-(oxycarbonyl(2-(3-(4-quinolinyl)propyl)hydrazono) erythromycin was prepared as follows:
STAGE A: Preparation of 11,12-dideoxy 6-O-methyl-12,11-(oxycarbonyl(2-hydrazono)) erythromycin (product P)
a) Condensation
A mixture of 3 g of 10,11-didehydro 11-deoxy 6-O-methyl erythromycin 2′-acetate 12-(1H-imidazole-1-carboxylate 4″-(phenylmethylcarbonate), 3 ml of hydrazine hydrate, 30 ml of acetonitrile and 492 mg of caesium carbanate is plunged in a bath at 80° C. for 10 mn, followed by concentrating to dryness, taking up in methylene chloride, washing with water, drying, filtering and bringing to dryness.
b) Deacetylation
3 g of the product obtained is dissolved in 30 ml of methanol and agitation is carried out at ambient temperature for 15 hours followed by concentration to dryness 2.7 g of deacetylated product is obtained.
c) Hydrogenolysis
The product obtained in Stage b) is dissolved in 100 ml of methanol. Hydrogeneolysis is carried out in the presence of 600 mg of 10% palladium on activated charcoal, followed by filtering, rinsing with methanol and methylene chloride then the filtrate is concentrated to dryness. 2.52 g of a product is obtained which is purified by eluting with an isopropryl ether-menthanol-triethylamine mixture (80-10-10). 941.8 mg of a product is obtained which is chromatographed again eluting with an isopropyl ether-methanol-triethylamine mixture (80-10-10). In this way 761 mg of 6-O-methyl-12,11-(oxycarbonyl) (2-hydrazono)) erythromycin is obtained.
Microanalysis Calculated Found
C % 59.45 56.8
H % 8.83 8.5
N % 5.33 5.2
Mass spectrum
788° = MH+
810° = MNa+
STAGE B: 11,12-dideoxy 6-O-methyl 12,11-(oxycarbonyl-(2-(3-(4-quinolinyl)propyl)hydrazono) erythromycin
A mixture of 230 mg of the product obtained in Stage A above, 5 ml of methanol, 0.3 g of quinoline 4-propanal, 0.055 ml of acetic acid is agitated for 15 hours of ambient temperature. 0.065 g of sodium cyanoborohydride is added. Agitation is carried out at ambient temperature for 24 hours. The methanol is evaporated off, followed by extracting with ethyl acetate, washing with soda solution then with water, drying, filtering and evaporating to dryness. 220 mg of a product is obtained which is chromatographed on silica, eluting with an ethyl acetate-triethylamine mixture (95-5). 80 mg of the sought product is obtained.
Microanalysis Calculated Found
C % 63.99 64.1
H % 8.42 8.3
N % 5.85 5.7
Mass spectrum
163° = OH in position 2′
957° = (M*H)*
979° = (M*Na)*
EXAMPLE 2 11,12-dideoxy-3-d((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribohexopyranosyl) oxy)-3-hydroxy-6-O-methyl-12,11-(oxycarbonyl((4-(4-(3-pyridinyl)-1H-imidazol-1-yl)-butyl)imino))-erythromycin
By operating as in Example 1 starting with 11,12-dideoxy-6-O-methyl-12,11-(oxycarbonyl((4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)imino))-erythromycin, the sought product was obtained. M.p.=210° C.
The starting product namely 11,12-dideoxy-6-O-methyl-12,11-(oxycarbonyl((4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)imino))-erythromycin was prepared according to the process indicated above the preparation of the starting product of Example 1.
Example of Pharmaceutical Composition
Compounds were prepared containing:
Product of Example 1 150 mg
Excipient s.q.f. 1 g
Detail of excipient: starch, talc, magnesium sterate
Pharmacological Study of the Products of the Invention
Method of Dilutions in Liquid Medium
A series of tubes were prepared into which the same quantity of sterile nutritive medium is distributed. Increasing quantities of the product to be studied are distributed into each tube, then each tube is seeded with a bacterial strain. After incubation for twenty-four hours in a heating chamber at 37° C., the growth inhibition is evaluated by transillumination, which permits the minimal inhibitory concentrations (M.I.C.) to be determined, expressed in micrograms/cm3.
The following results were obtained:
GRAM + bacterial strains
Products Ex. 1 Ex. 2
Staphylococtus aureus 011UC4 0.3 —
Staphylococtus aureus 011G0251
Staphylococtus epidermidis 012G0111
Streptoccocus pyogenes group A 0.04 0.15
02A1UCI
Streptoccocus agalactae group B ≦0.02 0.04
02B1UTI
Streptoccocus faecalis group C 0.04 0.3
02D2UCI
Streptoccocus faecium group D 0.04 0.3
02D2UCI
Streptoccocus sp. group G 0.04 0.15
02GRGR5
Streptoccocus aritis 02mmCH1 0.3 0.34
Streptoccocus aritis 02mmGR01 0.15 0.6
Streptoccocus agalactae group B 0.6 1.2
02B1811
Streptoccocus pneumoniae 031515 0.6 1

Claims (15)

We claim:
1. A compound selected from the group consisting of (a)
Figure USRE038520-20040518-C00013
wherein X is selected from the group consisting of —CH2—, —SO2—SO2 — and —O—, Y is —(CH2)m—(CH═CHn)—CH2)o— —(CH 2)m—(CH═CH)n—(CH 2)o —, m+N+n+o≦8, n is 0 or 1, Ar is aryl or heterocycle aryl, the aryl and heterocycle aryl being unsubstituted or substituted with at least one substituent selected from the group consisting of —OH, halogen, —NO2, —CN, alkyl, alkenyl and alkynyl of up to 12 carbon atoms, optionally substituted with at least one halogen, alkoxy, alkenyloxy and alkynyloxy of up to 12 carbon atoms optionally substituted with at least one halogen, alkylthio, alkenylthio and alkynylthio of up to 12 carbon atoms optionally substituted with at least one halogen, N-alkyl, N-alkenyl and N-alkynyl of up to 12 carbon atoms optionally substituted with at least one halogen,
Figure USRE038520-20040518-C00014
Ra and Rb are individually hydrogen or alkyl of 1 to 12 carbon atoms, R3 is selected from the group consisting of 1 to 12 carbon atoms, aryl and heteroaryl, W is hydrogen or
Figure USRE038520-20040518-C00015
R″ is alkyl of 1 to 8 carbon atoms or Ar is unsubstituted or substituted aryl, the substituents being at least one member of the group consisting of —OH, halogen, —NO2, —CN, alkyl, alkenyl or alkynyl, O-alkyl, O-alkenyl, O-alkynyl, S-alkyl, S-alkenyl, S-alkynyl, N-alkyl, N-alkenyl and N-alkynyl containing up to 12 carbon atoms optionally substituted by at least one halogen, Z is hydrogen or acyl of an organic carboxylic acid and non-toxic, pharmaceutically acceptable acid addition salts of the compound of Formula I; and (b) 11,12 -dideoxy- 3 -de(( 2,6 -dideoxy- 3 -C-methyl- 3 -O-methyl-alpha-L-ribohexopyranosyl)oxy)- 3 -hydroxy- 6 -O-methyl- 12,11 -(oxycarbonyl( 2 -( 3 -( 4 -quinolinyl)propyl)hydrazono))-erythromycin.
2. A compound of claim 1 selected from the group consisting of -11,12-dideoxy-3-de((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribohexopyranosyl)oxy)-3-hydroxy-6-O-methyl-12,11-(oxycarbonyl((4-(4-(3-pyridinyl)-1H-imidazol-1-yl)-butyl)imino))-erythromycin and -11,12-dideoxy-3-de((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribohexopyranosyl)oxy)-3-hydroxy-6-O-methyl-12,11-(oxycarbonyl(2-(3-(4-quinolinyl)propyl)hydrazono))erythromycin.
3. Pharmaceutical compositions containing at least one medicament according to claim 1 as active ingredient.
4. A process for the preparation of a compound of claim 1 comprising reacting a compound of the formula
Figure USRE038520-20040518-C00016
wherein X, Y and Ar are defined in claim 1 with an acid to obtain a compound of the formula
Figure USRE038520-20040518-C00017
wherein X, Y and Ar are defined as above and optionally reacting the latter with an esterification agent or with an agent capable of introducing the carbamate radical.
5. A method of treating bacterial infections in a warm-blooded animal comprising administering to a warm-blooded animal a bactericidally effective amount of a compound of claim 1.
6. The method of claim 5 wherein the compound is selected from the group consisting of -11,12-dideoxy-3-de((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribohexopyranosyl) oxy)-3-hydroxy-6-O-methyl-12,11-(oxycarbonyl((4-(4-(3-pyridinyl)-1H-imidazol-1-yl)-butyl)imino))-erythromycin and -11,12-dideoxy-3-de((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribohexopyranosyl)oxy)-3-hydroxy-6-O-methyl-12,11-(oxycarbonyl(2-(3-(4-quinolinyl)propyl)hydrazono))-erythromycin.
7. A compound of claim 1 wherein Z is hydrogen.
8. A compound of claim 1 wherein w is hydrogen.
9. A compound of claim 1 wherein X is —CH2.
10. A compound of claim 1 wherein Y is —(CH2)n and n is 2 or 4 or 5 —(CH 2)3—, —(CH 2)4—, or —(CH 2)5—.
11. A compound of claim 1 wherein Rr is heterocyclic aryl.
12. A compound of claim 11 1wherein Ar is 4-quinolinyl mono or polysubstituted.
13. A compound of claim 11 1wherein Ar is unsubstituted 4-quinolinyl.
14. A compound of claim 1 wherein Ar is optionally substituted
Figure USRE038520-20040518-C00018
15. A bactericidally effective amount of a compound claim 1 and an inert pharmaceutical carrier.
US09/838,628 1996-02-28 1997-02-27 Erythromycin derivatives, method for preparing same, and use thereof as drugs Expired - Lifetime USRE38520E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/838,628 USRE38520E1 (en) 1996-02-28 1997-02-27 Erythromycin derivatives, method for preparing same, and use thereof as drugs

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9602472A FR2745290B1 (en) 1996-02-28 1996-02-28 NOVEL ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS
FR9602472 1996-02-28
US09/125,959 US6096714A (en) 1996-02-28 1997-02-27 Erythromycin derivatives, method for preparing same, and use thereof as drugs
US09/838,628 USRE38520E1 (en) 1996-02-28 1997-02-27 Erythromycin derivatives, method for preparing same, and use thereof as drugs
PCT/FR1997/000351 WO1997031929A1 (en) 1996-02-28 1997-02-27 Novel erythromycin derivatives, method for preparing same, and use thereof as drugs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/125,959 Reissue US6096714A (en) 1996-02-28 1997-02-27 Erythromycin derivatives, method for preparing same, and use thereof as drugs

Publications (1)

Publication Number Publication Date
USRE38520E1 true USRE38520E1 (en) 2004-05-18

Family

ID=32302965

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/838,628 Expired - Lifetime USRE38520E1 (en) 1996-02-28 1997-02-27 Erythromycin derivatives, method for preparing same, and use thereof as drugs

Country Status (1)

Country Link
US (1) USRE38520E1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0487411A1 (en) * 1990-11-21 1992-05-27 Roussel Uclaf Erythromycin derivatives, their preparation, intermediates obtained and their application as medicaments
EP0716093A1 (en) * 1994-12-09 1996-06-12 Roussel Uclaf Erythromycin derivatives, their process of preparation and application as medicaments

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0487411A1 (en) * 1990-11-21 1992-05-27 Roussel Uclaf Erythromycin derivatives, their preparation, intermediates obtained and their application as medicaments
US5444051A (en) * 1990-11-21 1995-08-22 Roussel Uclaf Erythromycin compounds
EP0716093A1 (en) * 1994-12-09 1996-06-12 Roussel Uclaf Erythromycin derivatives, their process of preparation and application as medicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LeMahieu et al. J. Med. Chem. 1974, 17(9), 953-956. *

Similar Documents

Publication Publication Date Title
US6096714A (en) Erythromycin derivatives, method for preparing same, and use thereof as drugs
US5747467A (en) Erythromycins
JPH05132497A (en) O-methyl derivative of azithromycin a, preparation thereof, intermediate thereof and application thereof as medicine
AU697876B2 (en) New erythromycin derivatives, their preparation process and their use as medicaments
US6455505B2 (en) Derivatives . . . use as medicaments
US6313101B1 (en) Derivatives of erythromycin, their preparation process and their use as medicaments
CA2301643A1 (en) 6,9-bridged erythromycin derivatives
US6420535B1 (en) 6-O-carbamate ketolide derivatives
US6034069A (en) 3-'N-modified 6-O-substituted erythromycin ketolide derivatives having antibacterial activity
US6433151B1 (en) Erythromycin derivatives, a process for their preparation and their use as medicaments
AP1078A (en) Novel erythromycin derivatives, method for preparing same and use thereof as drugs.
AP997A (en) Novel erythromycin derivatives, method for preparing them and their use as medicine.
EP1181300B1 (en) 6-o-carbamate ketolide derivatives
US5747466A (en) 3-deoxy-3-descladinose derivatives of erythromycins A and B
USRE38520E1 (en) Erythromycin derivatives, method for preparing same, and use thereof as drugs
US6706692B1 (en) 6-deoxy erythromycin derivatives, method for preparing same and use as medicines
AU714176B2 (en) 3-deoxy-3-descladinose derivatives of erythromycins A and B
KR20000062286A (en) Novel Erythromycin Derivatives, Method of Preparation and Application as Medicines
HK1021537B (en) 6-o-substituted ketolides having antibacterial activity
MXPA99005840A (en) Novel erythromycin derivatives, method of preparation and application as medicines

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 12